The potential of endothelin antagonism as a therapeutic approach

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• BLOCH KD, HONG CC, EDDY RL, SHOWS TB, QUERTERMOUS T: cDNA cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal contractor peptide is rat endothelin 2. Cenoinics (1991) 10:236–242.
   Google Scholar
• CUNNINGHAM ME, HURIBAL M, BALA RJ, McMILLEN MA: Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Grit. Care Med. (1997) 25:958–964.
   PubMed Web of Science ®Google Scholar
• MALEK A, IZUMO S: Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Ain. Physic] (1992) 263:C389–C396.
   PubMed Web of Science ®Google Scholar
• BARTON M, SHAW S, D'USCIO LV, MOREAU P, LUSCHER TF: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem. Biophys. Res. Commun. (1997) 238:861–865.
   PubMed Web of Science ®Google Scholar
• MATSUURA A, YAMOCHI W, HIRATA K, KAWASHIMA S, YOKOYAMA M: Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension (1998) 32:89–95.
   PubMed Web of Science ®Google Scholar
• CORDER R, CARRIER M, KHAN N, KLEMM P, VANE JR: Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J. Cardiovasc. Pharmacol (1995) 26\(Suppl. 3):S56–S58.
   Google Scholar
• SCHWARTING A, SCHLAAK J, LOTZ J et al: Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). Land. Rheumatol. (1996) 25:246–256.
   Web of Science ®Google Scholar
• OHKITA M, TAKAOKA M, SUGII M, SHIOTA Y, NOJIRI R, MATSUMURA Y: The role of nuclear factor-KB in the regulation of endothelin-1 production by nitric oxide. Eur. Pharmacol (2003) 472:159–164.
   PubMed Web of Science ®Google Scholar
• BENIGNI A: Endothelin antagonists in renal disease. Kidney mt. (2000) 57:1778–1794.
   PubMed Web of Science ®Google Scholar
• WADA A, TSUTAMATO T, MAEDA Y, KANAMORI T, MATSUDA Y, KINOSHITA M: Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am..]: Physiol (1996) 270:H1819–H1824.
   Google Scholar
• QUEHENBERGER P, BIERHAUS A, FASCHING P et al.: Endothelin 1 transcription is controlled by nuclear factor-KB in AGE-stimulated cultured endothelial cells. Diabetes (2000) 49:1561–1570.
   PubMed Web of Science ®Google Scholar
• LEE ME, BLOCH KD, CLIFFORD JA, QUERTERMOUS T: Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J. Biol. Chem. (1990) 265:10446–10450.
   Google Scholar
• MAWJI IA, ROBB GB, TAI SC, MARSDEN PA: Role of the 3'-untranslated region of human endothelin-1 in vascular endothelial cells. Contribution to transcript liability and the cellular heat shock response. J. Biol. Chem. (2004) 279:8655–8667.
   Google Scholar
• ••Elegant paper with a sophisticatedmethodology that contributes significantly to our understanding of the transcriptional regulation of ET1 gene.
   Google Scholar
• SCHWEIZER A, VALDENAIRE 0, NELBOCK P et al.: Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem. J. (1997) 328:871–877.
   Google Scholar
• XU D, EMOTO N, GIAID A et al.: ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell (1994) 78:473–485.
   PubMed Web of Science ®Google Scholar
• RUSSELL FD, SKEPPER JN, DAVENPORT AP: Human endothelial cell storage granules. A novel intracellular site for isoforms of the endothelin-converting enzyme. Circ. Res. (1998) 83:314–321.
   Google Scholar
• RUSSELL FD, SKEPPER JN, DAVENPORT AP: Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. Cardiovasc. Pharmacol. (1998) 31:424–430.
   PubMed Web of Science ®Google Scholar
• KITAMURA K, TOMITA K: Endothelin receptor antagonists prevent parathyroid cell proliferation caused by hypocalcemia in rats. Curr. Opin. Nephrol Hypertens. (2002) 11:411–415.
   PubMed Web of Science ®Google Scholar
• WAGNER OF, CHRIST G, WOJTA J et al.: Polar secretion of endothelin-1 by cultured endothelial cells. Biol. Chem. (1992) 267:16066–16068.
   Web of Science ®Google Scholar
• ZOJA C, MORIGI M, F1GLIUZZI M et al.: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. I Kidney Dis. (1995) 26:934–941.
   Google Scholar
• ARAI H, HORT S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730–732.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, YANAGISAWA M, TAKUWA Y et al.: Cloning of a cDNA encoding a non-isopeptide-selective subtype of endothelin receptor. Nature (1990) 348:732–735.
   PubMed Web of Science ®Google Scholar
• LEVIN ER: Endothelins. N Engl. I Med.(1995) 333:356–363.
   PubMed Web of Science ®Google Scholar
• MANGELUS M, GALRON R, NAOR Z, SOKOLOVSKY M: Involvement of nuclear factor-kappaB in endothelin-A-receptor-induced proliferation and inhibition of apoptosis. Cell. Mol. Neurobiol (2001) 21:657–674.
   PubMed Web of Science ®Google Scholar
• MORELAND S, McMULLEN DM, DELANEY CL, LEE VG, HUNT JT: Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem. Biophys. Res. Commun. (1992) 184:100–106.
   PubMed Web of Science ®Google Scholar
• FUKURODA T, FUJIKAWA T, OZAKI S,ISHIKAWA K, YANO M, NISHIKIBE M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. (1994) 199:1461–1465.
   PubMed Web of Science ®Google Scholar
• SAIJONMAA 0, NYMAN T, FYHRQUIST F: Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem. Biophys. Res. Commun. (1992) 188:286–291.
   PubMed Web of Science ®Google Scholar
• IWASAKI S, HOMMA T, MATSUDA Y, KON V: Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J. Biol. Chem. (1995) 270:6997–7003.
   PubMed Web of Science ®Google Scholar
• SIMONSON MS, HERMAN WH: Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G 1430 Expert Op/n. Investig. Drugs (2004) 13(11) protein-coupled receptors and pp60c-src. J. Biol. Chem. (1993) 268:9347–9357.
   Google Scholar
• BENIGNI A, REMUZZI G: Endothelinantagonists. Lancet (1999) 353:133–138.
   PubMed Web of Science ®Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON SEGESSER L, LUSCHER TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• TABUCHI Y, NAKAMARU M, RAKUGI H, NAGANO M, MIKAMI H, OGIHARA T: Endothelin inhibits presynaptic adrenergic neurotransmission in rat mesenteric artery. Biochem. Biophys. Res. Commun. (1989) 161:803–808.
   PubMed Web of Science ®Google Scholar
• SCHIEBINGER RJ, GOMEZ-SANCHEZ CE: Endothelin: a potent stimulus of atrial natriuretic peptide secretion by superfused rat atria and its dependency on calcium. Endocrinology (1990) 127:119–125.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, NOLL G, LUSCHER TF: Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am. J. Cardiovasc. Drugs (2001) 1:293–303.
   PubMedGoogle Scholar
• MILLER WL, REDFIELD MM, BURNETT JC: Integrated cardiac, renal, and endocrine actions of endothelin. Chi]. Invest. (1989) 83:317–320.
   PubMed Web of Science ®Google Scholar
• GURBANOV K, RUBINSTEIN I, HOFFMAN A, ABASSI Z, BETTER OS, WINAVER J: Differential regulation of renal regional blood flow by endothelin-1. Am. J. Physiol (1996) 271:F1166–F1172.
   PubMed Web of Science ®Google Scholar
• GARCIA NH, GARVIN JL: Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade. J. Chi]. Invest. (1994) 93:2572–2577.
   PubMed Web of Science ®Google Scholar
• EIAM-ONG S, HILDEN SA, KING AJ, JOHNS CA, MADIAS NE: Endothelin-1 stimulates the Na-IFT* and NaVHCO3 transporters in rabbit renal cortex. Kidney Int. (1992) 42:18–24.
   PubMed Web of Science ®Google Scholar
• GUNTUPALLI J, DUBOSE TD Jr: Effects of endothelin on rat renal proximal tubule cotransport and Na-IFT* exchange. Am. J. Physiol (1994) 266:F658–F666.
   PubMed Web of Science ®Google Scholar
• PLATO CF, GARVIN JL: Nitric oxide, endothelin and nephron transport: potential interactions. OM Exp. Pharmacol Physiol (1999) 26:262–268.
   PubMed Web of Science ®Google Scholar
• PERICO N, PLATA CORNEJO R, BENIGNI A, MALANCHINI B, LADNY JR, REMUZZI G: Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase. J. Am. Soc. Nephrol (1991) 2:57–69.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM, OPGENORTH TJ: ETA receptor-mediated responses to endothelin-1 and big endothelin-1 in the rat kidney. Br. J. Pharmacol (1994) 111:729–732.
   PubMed Web of Science ®Google Scholar
• HOFFMAN A, ABASSI ZA, BRODSKY S, RAMADAN R, WINAVER J: Mechanisms of big endothelin-l-induced diuresis and natriuresis : role of ET(B) receptors. Hypertension (2000) 35:732–739.
   PubMed Web of Science ®Google Scholar
• UZUNER K, BANKS RO: Endothelin-induced natriuresis and diuresis are pressure-dependent events in the rat. Am. J. Physiol (1993) 265:R90–R96.
   PubMed Web of Science ®Google Scholar
• SIMONSON MS, DUNN MJ: Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates 0-adrenergic-mediated cyclic adenosine monophosphate accumulation. J. OM Invest. (1990) 85:790–797.
   PubMed Web of Science ®Google Scholar
• ACHMAD T, RAO G: Chemotaxis of human blood monocytes towards endothelin-1 and the influence of calcium channel blockers. Biochem. Biophys. Res. Commun. (1992) 189:994–1000.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, RUGGENENTI P, BENIGNI A: Understanding the nature of renal disease progression. Kidney Int. (1997) 51:2–15.
   PubMed Web of Science ®Google Scholar
• McCULLOCH KM, DOCHERTY C, MacLEAN MR: Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. BE J. Pharmacol (1998) 123:1621–1630.
   PubMed Web of Science ®Google Scholar
• HORGAN MJ, PINHEIRO JM, MALIK AB: Mechanism of endothelin-1-induced pulmonary vasoconstriction. Circ. Res. (1991) 69:157–164.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, STEWART DJ, CERNACEK P, GOSSELIN G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation (1996) 94:1578–1584.
   PubMed Web of Science ®Google Scholar
• LEVIN ER, FRANK HJ, PEDRAM A: Endothelin receptors on cultured fetal rat diencephalic glia. Neurochem. (1992) 58:659–666.
   PubMed Web of Science ®Google Scholar
• VIGNE P, LOPEZ FARRE A, FRELIN C: Na(1-K(1-C1 cotransporter of brain capillary endothelial cells. Properties and regulation by endothelins, hyperosmolar solutions, calyculin A, and interleukin-1. J. Biol. Chem. (1994) 269:19925–19930.
   Google Scholar
• YAMAMOTO T, KIMURA T, OTA K et al: Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am..! Physiol (1992) 262:E856–E862.
   PubMed Web of Science ®Google Scholar
• SAMSON WK, MURPHY TC: Antidipsogenic actions of endothelins are exerted via the endothelin-A receptor in the brain. Am. J. Physiol (1993) 265:R1212–R1215.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, HIRATA Y, KANNO K, OHTA K, EMORI T, MARUMO F: Effect of endothelin-1 on release of arginine-vasopressin from perifused rat hypothalamus. Biochem. Biophys. Res. Commun. (1989) 163:1332–1337.
   PubMed Web of Science ®Google Scholar
• KANYICSKA B, BURRIS TP, FREEMAN ME: Endothelin-3 inhibits prolactin and stimulates LH, FSH and TSH secretion from pituitary cell culture. Biochem. Biophys. Res. Commun. (1991) 174:338–343.
   PubMed Web of Science ®Google Scholar
• DAVAR G, HANS G, FAREED MU, SINNOTT C, STRICHARTZ G: Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport (1998) 9:2279–2283.
   PubMed Web of Science ®Google Scholar
• IHARA M, NOGUCHI K, SAEKI T et al: Biological profiles of highly potent novel endothelin antagonists for the ETA receptor. Life ScL (1992) 50:247–255.
   PubMed Web of Science ®Google Scholar
• ARAMORI I, NIREI H, SHOUBO M et al: Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol (1993) 43:127–131.
   PubMed Web of Science ®Google Scholar
• WEBB ML, BIRD JE, LIU EC et al: BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. Pharmacol Exp. Ther. (1995) 272:1124–1134.
   PubMed Web of Science ®Google Scholar
• LLOYD I: Pharma Project (Version 2, I). PJB Publications Ltd., London, UK, (1999).
   Google Scholar
• CLOZEL M, BREU V, BURRI K et al: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365:759–761.
   PubMed Web of Science ®Google Scholar
• NISHIKIBE M, TSUCHIDA S, OKADA M et al: Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. (1993) 52:717–724.
   PubMed Web of Science ®Google Scholar
• ORTIZ MC, SANABRIA E, MANRIQUEZ MC, ROMERO JC, JUNCOS LA: Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension (2001) 37:505–510.
   PubMed Web of Science ®Google Scholar
• MOREAU P, D'USCIO LV, SHAW S, TAKASE H, BARTON M, LUSCHER TF: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation (1997) 96:1593-1597.77.
   Google Scholar
• HERIZI A, JOVER B, BOURIQUET N, MIMRAN A: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension (1998) 31:10–14.
   PubMed Web of Science ®Google Scholar
• LI JS, KNAFO L, TURGEON A, GARCIA R, SCHIFFRIN EL: Effect of78.endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am. J. Physic] (1996) 271:H88–H93. 77.
   Google Scholar
• EHMKE H, FAULHABER J, MUNTER K, KIRCHENGAST M,79.WIESNER RJ: Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension (1999) 33:954–960.
   Google Scholar
• SORENSEN SS, EGEBLAD M, EISKJAER H et al.: Endothelin in renovascular and essential hypertension.80.Blood Press (1994) 3:364–369.
   Google Scholar
• MATSUMURA Y, HASHIMOTO N, TAIRA S et al: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone81.acetate-salt-induced hypertension in rats. Hypertension (1999) 33:759–765.
   PubMed Web of Science ®Google Scholar
• BLEZER EL, NICOLAY K,82. GOLDSCHMEDING R et al: Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke- prone hypertensive rats. Hypertension (1999) 33:137–144.83.
   Google Scholar
• COSENZI A, BERNOBICH E, BONAVITA M, BERTOLA G, TREVISAN R, BELLINI G: Antihypertensive treatment with enrasentan (513217242) in an animal model of hypertension and hyperinsulinemia.84.Cardiovasc. Pharmacol (2002) 39:488–495.
   PubMed Web of Science ®Google Scholar
• MOREAU P, TAKASE H, KUNG CF, SHAW S, LUSCHER TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension (1997) 29:763–769.
   PubMed Web of Science ®Google Scholar
• THARAUXPL, CHATZIANTONIOU C, CASELLAS D, FOUASSIER L, ARDAILLOU R, DUSSAULE JC: Vascular endothelin-1 gene expression and synthesis and effect on renal Type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation (1999) 99:2185–2191.
   PubMed Web of Science ®Google Scholar
• SVENTEK P, TURGEON A, SCHIFFRIN EL: Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation (1997) 95:240–244.
   PubMed Web of Science ®Google Scholar
• FORTEPIANI LA, JAN VIER JJ, ORTIZ MC, ATUCHA NM, GARCIA-ESTAN J: Effect of endothelin blockade on pressure natriuresis in nitric oxide-deficient hypertensive rats. Hypertens. (1999) 17:287–291.
   Web of Science ®Google Scholar
• SHARIFI AM, HE G, TOUYZ RM, SCHIFFRIN EL: Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. Cardiovasc. Pharmacol (1998) 31\(Suppl. 0:5309–5312.
   Google Scholar
• LAROUCHE I, SCHIFFRIN EL: Cardiac microvasculature in DOCA-salt hypertensive rats : effect of endothelin ET(A) receptor antagonism. Hypertension (1999) 34:795–801.
   PubMed Web of Science ®Google Scholar
• CHEN YF, OPARIL S: Endothelin and pulmonary hypertension. J. Cardiovasc. Pharmacol. (2000) 35:S49–S53.
   PubMed Web of Science ®Google Scholar
• OPARIL S, CHEN SJ, MENG QC, ELTON TS, YANO M, CHEN YF: Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am. J. Physiol (1995)268:L95–L100.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, CHEN YF, MENG QC, DURAND J, DICARLO VS, OPARIL S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physic] (1995) 79(6):2122–2131.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, CHEN YF, OPGENORTH TJ et al.: The orally active nonpeptide endothelin-A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J. Cardiovasc. Pharmacol (1997) 29 (6) :713–725.
   PubMed Web of Science ®Google Scholar
• CERNACEK P, STEWART DJ, MONGE JC, ROULEAU JL: The endothelin system and its role in acute myocardial infarction. Can. j Physiol Pharmacol (2003) 81:598–606.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M, YAMAGUCHI I, GOTO K, SUGISHITA Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384:353–355.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI T,YAMAGUCHI I, GOTO K, SUGISHITA Y: Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist. ./. Cardiovasc. Pharmacol (1998) 31 (Suppl. 0:5302–5305.
   Google Scholar
• WADA A, TSUTAMOTO T, FUKAI D et al.: Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J. Am. Coll. Cardiol. (1997) 30:1385–1392.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA M, YASUE H, OKUMURA K et al.: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation (1993) 87:464–469.
   PubMed Web of Science ®Google Scholar
• MOE GW, ALBERNAZ A, NAIK GO, KIRCHENGAST M, STEWART DJ: Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc. Res. (1998) 39:571–579.
   PubMed Web of Science ®Google Scholar
• SCHIRGER JA, CHEN HH, JOUGASAKI M et al: Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation (2004) 109:249–254.
   PubMed Web of Science ®Google Scholar
• •An important piece of work demonstrating that activation of the ET-1 system precedes RAS activation in experimental congestive heart failure.
   Google Scholar
• SPINALE F, WALKER J, MUKHERJEE R, IANNINI J, KEEVER A, GALAGHER K: Concomitant endothelin receptor subtype-A blockade during the progression of pacing induced congestive heart failure in rabbits: beneficial effects on left ventricular and myocyte function. Circulation (1997) 95:1918-1929. 1432Expert Op/n. Investig. Drugs (2004) 13(11)
   Google Scholar
• BORGESON DD, GRANTHAM JA, WILLIAMSON EE et al.: Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension (1998) 31:766–770.
   PubMed Web of Science ®Google Scholar
• OHNISHI M, WADA A, TSUTAMOTO T, FUKAI D, KINOSHITA M: Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Cardiovasc. Res. (1998) 39:617–624.
   PubMed Web of Science ®Google Scholar
• TEERLINK J, LOFFLER B, HESS P, MARIE J, CLOZEL M, CLOZEL J: Role of endothelin in the maitenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation (1994) 9:2510–2518.
   Google Scholar
• GROVER GJ, DZWONCZYK S, PARHAM CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. (1993) 27:1613–1618.
   PubMed Web of Science ®Google Scholar
• PERNOW J, FRANCO-CERECEDA A, MATRAN R, LUNDBERG JM: Effect of endothelin-1 on regional vascular resistances in the pig. J. Cardiovasc. Pharmacol (1989) 13\(Suppl. 5):S205–S206.
   Google Scholar
• GELLAI M, JUGUS M, FLETCHER T, DEWOLF R, NAMBI P: Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat. J. Clia Invest. (1994) 93:900–906.
   PubMed Web of Science ®Google Scholar
• BIRCK R, KNOLL T, BRAUN C et al: Improvement of postischemic acute renal failure with the novel orally active endothelin-A receptor antagonist LU 135252 in the rat. J. Cardiovasc. Pharmacol (1998) 32:80–86.
   PubMed Web of Science ®Google Scholar
• LANGMAN LJ, YATSCOFF RW: Comparison of the effects of cyclosporin G (0G37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cells lines. Ther. Drug Monit. (1994) 16:450–457.
   PubMed Web of Science ®Google Scholar
• IWASAKI S, HOMMA T, KON V: Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney In] (1994) 45:592–597.
   PubMed Web of Science ®Google Scholar
• PERICO N, DADAN J, REMUZZI G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol (1990) 1:76–83.
   PubMed Web of Science ®Google Scholar
• BROOKS DP, CONTINO LC: Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670. Eur. Pharmacol (1995) 294:571–576.
   PubMed Web of Science ®Google Scholar
• KON V, HUNLEY TE, FOGO A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II affects fibrosis. Transplantation (1995) 60:89–95.
   PubMed Web of Science ®Google Scholar
• HEYMAN SN, CLARK BA, KAISER N et al.: Radiocontrast agents induce endothelin release in vivo and in vitro. Am. Soc. Nephrol (1992) 3:58–65.
   PubMed Web of Science ®Google Scholar
• OLDROYD S, SLEE SJ, HAYLOR J, MORCOS SK, WILSON C: Role for endothelin in the renal responses to radiocontrast media in the rat. Chu. Se (1994) 87:427–434.
   Google Scholar
• POLLOCK DM, POLAKOWSKI JS, WEGNER C, OPGENORTH TJ: Beneficial effect of ETA receptor blockade in rat model of radiocontrast-induced nephropathy. Ren. Fail. (1997) 19:753–761.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, PERICO N, GASPARI F et al.: Increased renal endothelin production in rats with reduced renal mass. Am. J. Physiol (1991) 260:F331–F339.
   PubMed Web of Science ®Google Scholar
• BRUZZI I, CORNA D, ZOJA C et al: Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am..]: Pathol (1997) 151:1241–1247.
   Google Scholar
• ZOJA C, LIU X-H, ABBATE M et al: Angiotensin II blockade limits tubular protein overreabsorption and the consequent up-regulation of endothelin-1 gene in experimental membranous nephropathy. Exp. Nephrol (1998) 6:121–131.
   PubMedGoogle Scholar
• FUKUI M, NAKAMURA T, EBIHARA I et al.: Gene expression for endothelins and their receptors in glomeruli of diabetic rats. Lab. Clin. Med. (1993) 122:149–156.
   PubMedGoogle Scholar
• MORABITO E, CORSICO N, SERAFINI S, MARTELLI EA: Elevated urinary excretion of endothelins in streptozotocin diabetic rats. Life Sci. (1994) 54:PL197-PL200.
   Google Scholar
• NAKAMURA T, EBIHARA I, FUKUI M et al: Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleoside-induced nephrosis. ./. Am. Soc. Nephrol (1995) 5:1585–1590.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, EBIHARA I, FUKUI M et al.: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W Fl mice. Rena] Physiol Biochem. (1993) 16:233–243.
   PubMedGoogle Scholar
• AL-NIMRI MA, KOMERS R, OYAMA TT, SUBRAMANYA AR, LINDSLEY JN, ANDERSON S: Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney In] (2003) 63:1776–1784.
   PubMed Web of Science ®Google Scholar
• HOCHER B, THONE-REINEKE C, ROHMEISS P et al: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. I Clia Invest. (1997) 99:1380–1389.
   PubMed Web of Science ®Google Scholar
• LIEFELDT L, BOCKER W, SCHONFELDER G, ZINTZ M, PAUL M: Regulation of the endothelin system in transgenic rats expressing the human endothelin-2 gene. J. Cardiovasc. Pharmacol (1995) 26:S32–S35.
   Web of Science ®Google Scholar
• BENIGNI A, ZOJA C, CORNA D et al: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney In] (1993) 44:440–444.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, ZOJA C, CORNA D et al: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. I Kidney Dis. (1996) 27:416–423.
   PubMed Web of Science ®Google Scholar
• NABOKOV A, AMANN K, WAGNER J, GEHLEN F, MUNTER K, RITZ E: Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial. Transplant. (1996) 11:514–520.
   PubMed Web of Science ®Google Scholar
• OKADA Y, NAKATA M, IZUMOTO H et al: Role of endothelin ETB receptor in partial ablation-induced chronic renal failure in rats. Eur. Pharmacol (2004) 494:63–71.
   PubMed Web of Science ®Google Scholar
• •Demonstration of a protective role of the ETB receptor in vascular and renal injury.
   Google Scholar
• NAKAMURA T, EBIHARA I, TOMINO Y, KOIDE H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. (1995) 47:481–489.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, EBIHARA I, FUKUI M, TOMINO Y, KOIDE H: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes (1995) 44(8):895–899.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, COLOSIO V, BRENA C, BRUZZI I, BERTANI T, REMUZZI G: Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes (1998) 47:450–456.
   PubMed Web of Science ®Google Scholar
• ORTH SR, ESSLINGER JP, AMANN K, SCHWARZ U, RASCHACK M, RITZ E: Nephroprotection of an ETA-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension (1998) 31:995–1001.
   PubMed Web of Science ®Google Scholar
• RODRIGUE ME, MOREAU C, LARIVIERE R, LEBEL M: Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J. Cardiovasc. Pharmacol (2003) 41:388–395.
   PubMed Web of Science ®Google Scholar
• GIANELLO P, FISHBEIN J, BESSE T et al.: Measurement of the vasoconstrictive substances endothelin, angiotensin II and tromboxane B, in cold storage solution can reveal previous renal ischemic insults Transplant mt. (1994) 7:11–16.
   Google Scholar
• HERRERO I, TORRAS J, RIERA M et al.: Prevention of cold ischaemia-reperfusion injury by an endothelin receptor antagonist in experimental renal transplantation. Nephrol Dial. Transplant. (1999) 14:872–880.
   PubMed Web of Science ®Google Scholar
• BRAUN C, VETTER S, CONZELMANN T et al: Improved recovery following posttransplant acute renal failure in rat renal isografts with an oral endothelin-A receptor antagonist. Exp. Nephrol. (2000) 8:283–290.
   PubMedGoogle Scholar
• WATSCHINGER B, SAYEGH MH: Endothelin in organ transplantation. Am. J. Kidney Dis. (1996) 27:151–161.
   PubMed Web of Science ®Google Scholar
• OKADA K, NISHIDA Y, MURAKAMI H et al: Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts. Antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation (1998) 97:2346–2351.
   Google Scholar
• BRAUN C, CONZELMANN T, VETTER S et al.: Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation (1999) 68:739–746.
   PubMed Web of Science ®Google Scholar
• ORTH SR, ODONI G, AMANN K, STRZELCZYK P, RASCHACK M, RITZ E: The ETA receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model. J. Am. Soc. Nephrol (1999) 10:387–391.
   PubMed Web of Science ®Google Scholar
• KOWALA MC, ROSE PM, STEIN PD et al: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol. (1995) 146:819–826.
   PubMed Web of Science ®Google Scholar
• BARTON M, HAUDENSCHILD CC, D'USCIO LV, SHAW S, MUNTER K, LUSCHER TF: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Nati Acad. Sci. USA (1998) 95:14367–14372.
   PubMed Web of Science ®Google Scholar
• CHADE AR, BEST PJ, RODRIGUEZ-PORCEL M et al: Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int. (2003) 64:962–969.
   PubMed Web of Science ®Google Scholar
• •An important report on the potential role of ET antagonists in renal injury in hypercholesterolaemia and atherosclerosis.
   Google Scholar
• VERMA S, LI SH, BADIWALA MV et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation (2002) 105: 1890-1896.
   Google Scholar
• OKADA M, KOBAYASHI M, MARUYAMA H et al.: Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol Physiol (1995) 22:763–768.
   PubMed Web of Science ®Google Scholar
• FERRO CJ, WEBB DJ: The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs (1996) 51:12–27.
   PubMed Web of Science ®Google Scholar
• WILLETTE RN, ZHANG H, MITCHELL MP et al: Non peptide endothelin antagonist: cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke (1994) 25:2450–2456.
   PubMed Web of Science ®Google Scholar
• KANESAKA Y, TOKUNAGA H, IWASHITA K, FUJIMURA S, NAOMI S, TOMITA K: Endothelin receptor antagonist prevents parathyroid cell proliferation of low calcium diet-induced hyperparathyroidism in rats. Endocrinology (2001) 142:407–413.
   PubMed Web of Science ®Google Scholar
• NORMAN P: Atrasentan Abbott. Curr. Opin. Investig. Drugs (2002) 3:1240–1248.
   Google Scholar
• YOKOKAWA K, TAHARA H, KOHNO M et al: Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann. Intern. Med. (1991) 114:213–215.
   PubMed Web of Science ®Google Scholar
• KRUM H, VISKOPER RJ, LACOURCIERE Y, BUDDE M, CHARLON V, INVESTIGATORS FTBH: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl. J. Med. (1998) 338:784–790.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, FERRO CJ, WEBB DJ: Bosentan in essential hypertension. N Engl. J. Med. (1998) 339:346.
   PubMedGoogle Scholar
• WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol Ther. (1996) 60:124–137.
   PubMed Web of Science ®Google Scholar
• HAYNES W, FERRO C, O'KANE K, SOMERVILLE D, LOMAX C, WEBB D: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 93:1860–1870.
   PubMed Web of Science ®Google Scholar
• NAKOV R, PFARR E, EBERLE S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am. I Hypertens. (2002) 15:583–589.
   PubMed Web of Science ®Google Scholar
• PLUMPTON C, FERRO CJ, HAYNES WG, WEBB DJ, DAVENPORT AP: The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br. Pharmacol (1996) 119:311–314.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• STRACHAN FE, SPRATT JC, WILKINSON IB, JOHNSTON NR, GRAY GA, WEBB DJ: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 33:581–585.
   PubMed Web of Science ®Google Scholar
• ERGUL S, PARISH DC, PUETT D, ERGUL A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension (1996) 28:652–655.
   PubMed Web of Science ®Google Scholar
• RIZZONI D, PORTERI E, CASTELLANO M et al.: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension (1996) 28:785–790.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ: Primary pulmonary hypertension. Chest (1993) 104:236–250.
   PubMed Web of Science ®Google Scholar
• RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl. I Med. (1992) 327:76–81.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, WALLMAN LL, JONES R et al.: Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 102:411–418.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON 0 et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358:1119–1123.
   Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl. I Med. (2002) 346:896–903.
   PubMed Web of Science ®Google Scholar
• GALIE N, HINDERLITER AL, TORBICKI A et al.: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. ./. Am. Coll. Cardiol (2003) 41:1380–1386.
   PubMed Web of Science ®Google Scholar
• GALIE N, MANES A, BRANZI A: The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. (2004) 61:227–237.
   PubMed Web of Science ®Google Scholar
• BARST RJ, IVY D, DINGEMANSE J et al: Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol Ther. (2003) 73:372–382.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, FROST A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. I Respir Grit. Care Med. (2004) 169:441–447.
   PubMed Web of Science ®Google Scholar
• LIEFELDT L, VAN GIERSBERGEN PL, DINGEMANSE J et al: Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am. I Kidney Dis. (2004) 43:923–926.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, PFEFFER MA: New therapeutic options in congestive heart failure: part I. Circulation (2002) 105:2099–2106.
   PubMed Web of Science ®Google Scholar
• MYLONA P, CLELAND JG: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur. J. Heart Fail (1999) 1:197–200.
   PubMed Web of Science ®Google Scholar
• KALRA PR, MOON JC, COATS AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol (2002) 85:195–197.
   Web of Science ®Google Scholar
• LOUIS A, CLELAND JG, CRABBE S et al: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology FL, USA (2001) Eur. J. Heart Fail 3:381–387.
   Google Scholar
• ANAND I, MCMURRAY J, COHN JN et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 364:347–354.
   PubMed Web of Science ®Google Scholar
• BINET I, WALLNOFER A, WEBER C, JONES R, THIEL G: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. (2000) 57:224–231.
   PubMed Web of Science ®Google Scholar
• GODDARD J, JOHNSTON NR, HAND MF et al: Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 109:1186–1193.
   PubMed Web of Science ®Google Scholar
• ONG AC, NEWBY LJ, DASH WOOD MR: Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp. Nephrol (2003) 93:e80.
   PubMed Web of Science ®Google Scholar
• OHUCHI T, KUWAKI T, LING GY et al: Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am../. Physiol. (1999) 276:R1071–R1077.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V: The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443. FEBS Lett. (1996) 383:42–45.
   PubMed Web of Science ®Google Scholar
• LIPA JE, NELIGAN PC, PERREAULT TM et al: Vasoconstrictor effect of endothelin-1 in human skin: role of ETA and ETB receptors. Am. I Physiol (1999) 276:H359–H367.
   PubMed Web of Science ®Google Scholar
• COWBURN PJ, CLELAND JG, MCARTHUR JD et al.: Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. (1999) 33:932–938.
   PubMed Web of Science ®Google Scholar
• CARDILLO C, KILCOYNE CM, WACLAWIW M, CANNON RO, 3RD, PANZA JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 33:753–758.
   PubMed Web of Science ®Google Scholar